Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
- Resource Type
- Article
- Authors
- Yamazaki, K.; Yamanaka, T.; Shiozawa, M.; Manaka, D.; Kotaka, M.; Gamoh, M.; Shiomi, A.; Makiyama, A.; Munemoto, Y.; Rikiyama, T.; Fukunaga, M.; Ueki, T.; Shitara, K.; Shinkai, H.; Tanida, N.; Oki, E.; Sunami, E.; Ohtsu, A.; Maehara, Y.; Yoshino, T.
- Source
- In Annals of Oncology January 2021 32(1):77-84
- Subject
- Gastrointestinal tumors
- Language
- ISSN
- 0923-7534